Explore the words cloud of the PrECISE project. It provides you a very rough idea of what is the project "PrECISE" about.
The following table provides information about the project.
TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT MBH
|Coordinator Country||Austria [AT]|
|Total cost||5˙695˙712 €|
|EC max contribution||3˙090˙312 € (54%)|
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
|Duration (year-month-day)||from 2016-01-01 to 2018-12-31|
Take a look of project's partnership.
|1||TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT MBH||AT (VILLACH)||coordinator||358˙125.00|
|2||UNIVERSITAETSKLINIKUM AACHEN||DE (AACHEN)||participant||620˙937.00|
|3||BAYLOR COLLEGE OF MEDICINE||US (HOUSTON TX)||participant||561˙250.00|
|4||TECHNISCHE UNIVERSITAT DARMSTADT||DE (DARMSTADT)||participant||539˙375.00|
|5||INSTITUT CURIE||FR (PARIS)||participant||535˙625.00|
|6||ASTRIDBIO TECHNOLOGIES KFT||HU (SZEGED)||participant||475˙000.00|
|7||EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH||CH (ZUERICH)||participant||0.00|
|8||EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH||CH (ZUERICH)||participant||0.00|
|9||IBM RESEARCH GMBH||CH (RUESCHLIKON)||participant||0.00|
|10||UNIVERSITAT ZURICH||CH (ZURICH)||participant||0.00|
Despite of their great promise, high-throughput technologies in cancer research have often failed to translate to major therapeutic advances in the clinic. One challenge has been tumour heterogeneity, where multiple competing subclones coexist within a single tumour. Genomic heterogeneity renders it difficult to identify all driving molecular alterations, and thus results in therapies that only target subsets of aggressive tumour cells. Another challenge lies in the integration of multiple types of molecular data into mathematical disease models that can make actionable clinical statements.
We aim to develop predictive computational technology that can exploit molecular and clinical data to improve our understanding of disease mechanisms and to inform clinicians about optimized strategies for therapeutic intervention. We propose to focus on prostate cancer, a leading cause of cancer death amongst men in Europe, but also prone to over-treatment. Our approach combines the exploitation of genomic, transcriptomic, proteomic, and clinical data in primary and metastatic tumours, prospective cohorts of well characterized prostate cancer patients, drug screenings in cell lines, and the use of the Watson technology, a last generation cognitive computer developed at IBM.
The translational objective of this study is to develop technology for identifying disease mechanisms and produce treatment recommendations for individual patients based on a therapeutic biomarker panel. The proposed software framework will be accessible through a graphical interface that will facilitate its dissemination and use by researchers, clinicians, and biomedical industries. The framework will provide intuitive tools to deposit, share, analyze, and visualize molecular and clinical data; as well as to infer prognosis, elucidate implicated mechanisms and recommend therapy accordingly. This software framework will serve as a proof of concept for future development by industrial partners in Europe.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRECISE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRECISE" are provided by the European Opendata Portal: CORDIS opendata.
eHealth Week 2016Read More
High Level eHealth Conference 2015Read More
Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076Read More